Navigation Links
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe

OSAKA, Japan, Oct. 1 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) - are part of Takeda's strategic global expansion efforts.

"Takeda has a significant opportunity to expand our presence in Mexico, Europe and other priority markets," said Alan MacKenzie, Executive Vice President (EVP) International Operations, Takeda Pharmaceuticals International, Inc. "Executing our territory expansion strategy is an important step toward further globalizing our operations and enhancing our ability to bring important medicines to patients who need them."

The Mexican pharmaceutical market is the 12th largest in the world and accounts for approximately 25 percent of the pharmaceutical sales throughout Latin America. The population in Mexico is increasing, and access to healthcare continues to grow, with the market increasing faster than in the United States and Europe, making it a key region for Takeda's expansion.

Nordics and Benelux are strategically important regions in Europe - Norway, Sweden, Denmark, Belgium and Luxembourg have a combined pharmaceutical market size which accounts for five percent of the European pharmaceutical market. Following the buy-back of Actos® (pioglitazone) in October 2008, Takeda will be distributing Actos in the five countries. The creation of these commercial subsidiaries will further increase Takeda's reach in the regions.

The Turkish pharmaceutical market is one of the largest global pharmaceutical markets, ranked sixth in Europe and 13th worldwide with the fastest forecasted growth rate in Europe over the next five years. Takeda also recently re-acquired the rights to Actos in this market, providing the business with a strong product with which to enter the market.

Overall, the new subsidiaries will accelerate Takeda's expansion efforts for core products including Actos and reinforces Takeda's global operating infrastructure. The company will work toward the earliest possible approval and launch of new products in these regions. Takeda's presence in these seven new countries builds upon other expansions announced in 2009 including commercial operations in Spain, Portugal, Ireland, and Canada.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Takeda is enhancing its R&D pipeline by concentrating its management resources in the following selected core therapeutic areas: lifestyle-related diseases, oncology and urological diseases (including gynecology), central nervous system diseases (including bone and joint disorders), and gastroenterological diseases. For more information, please visit

About Takeda Pharmaceuticals Mexico, S.A. de C.V.

    Name:           Takeda Pharmaceuticals Mexico, S.A. de C.V.
    Location:      Mexico city, Mexico
    Established:  October 2009

About Takeda Pharmaceuticals Nordics AB

    Name:           Takeda Pharmaceuticals Nordics AB
    Location:      Sweden
    Established:  October 2009

About Takeda Pharmaceuticals Benelux SPRL

    Name:           Takeda Pharmaceuticals Benelux SPRL
    Location:      Belgium
    Established:  October 2009

About Takeda Pharmaceuticals Trade, LLP

    Name:           Takeda Pharmaceuticals Trade, LLP
    Location:      Istanbul, Turkey
    Established:  October 2009

SOURCE Takeda Pharmaceutical Company Limited

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
2. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
3. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
4. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
5. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
8. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
9. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... -- Booth #3506 – Claymount is featuring its full line of ... Radiological Society of North America (RSNA) ... the Netherlands , Claymount is part of ... VAR ) and is one of the world,s leading suppliers ... exposure control systems for controlling dose during medical X-ray imaging. ...
(Date:12/1/2015)... WASHINGTON and TELTOW, Germany ... SensoMotoric Instruments (SMI) , a leading global manufacturer of ... RightEye LLC has included SMI remote eye trackers ... that help healthcare providers assess concussions, eye sight, and ... SMI RED -oem technology is part of SMI,s mass-market-ready ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... Rehabilitation P.C.went to NASDAQ to educate the personnel on spinal decompression therapy and ... the spine, a nonsurgical procedure. The benefits come from creating negative intradiscal pressure ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... detailing the important role that meat and poultry play in a healthy, ... poultry, a nutrition quiz where visitors can check their “meat IQ,” a section ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... World ... the Multi Jar, a container patent that allows for easier packing and organizing of ... US is worth $90 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:12/1/2015)... ... 01, 2015 , ... Henderson, a town of about 6,300 ... through a partnership this year with Aeneas Internet and Telephone. , With faster ... for entrepreneurs who want to build a business. Whether startups or long established ...
Breaking Medicine News(10 mins):